FAQ on Quantum BioPharma Ltd. and Unbuzzd Wellness's $5 Million Regulation D Offering

What is the purpose of Unbuzzd Wellness’s Regulation D 506(c) offering?

The purpose of the offering is to raise up to US$5 million to fund Unbuzzd Wellness’s growth and advance towards a potential initial public offering, as announced by Quantum BioPharma Ltd.

How does this offering affect Quantum BioPharma shareholders?

The capital raise will not dilute Quantum BioPharma shareholders due to an anti-dilution provision that maintains its 25% ownership in Unbuzzd until the beverage company reaches a $1 billion valuation.

What is Unbuzzd Wellness known for?

Unbuzzd Wellness is known for producing unbuzzd(TM), a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.

Who are the partners involved in Unbuzzd Wellness’s campaign?

Unbuzzd Wellness has partnered with MZ Digital and Dealmaker to run the campaign, which accepts both traditional and cryptocurrency investments.

What will the raised funds support?

According to CEO John Duffy, the raised funds will support direct-to-consumer, distributor, and retail expansion for Unbuzzd Wellness.

What is Quantum BioPharma Ltd.’s focus?

Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.

What is Lucid-MS?

Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Where can I find more information about Quantum BioPharma Ltd.?

The latest news and updates relating to Quantum BioPharma Ltd. (QNTM) are available in the company’s newsroom at https://ibn.fm/QNTM.